Ten leading companies are racing to commercialize Brain-Computer Interfaces across various access modes.
Here is a brief summary of the leading startups in the space:
@neuralink is the most heavily funded in the category at $1.29 billion cumulative capital backing. Its 1,024-electrode N1 array operates under the FDA-approved PRIME study, recently expanded to 21 participants. Targeting high-volume production and thousands of implants annually by 2030.
@synchroninc (US/Australia) offers the most advanced endovascular approach with its Stentrode; it closed a $200 million Series D, achieved Apple BCI HID integration, and is developing the Chiral cognitive foundation model with NVIDIA.
@BlackrockNeuro_ brings the longest clinical track record in implantable BCI, over 40 human implants since 2004. Its 96-channel Utah Array remains the academic research standard across published BCI literature. Tether acquired a majority stake for $200 million in 2024.
@PrecisionNeuro_ Neuroscience uses ultra-thin surface electrodes (1,024 channels per array, 4,096 demonstrated) and closed a $102 million Series C in December 2024; its lower-risk approach secured FDA 510(k) for its electrode arrays in April 2025.
@ScienceCorp_ is closest to Western commercialization with its PRIMA retinal implant; it raised $230 million in March 2026 and expects CE mark approval by mid-2026.
@paradromics achieved 200 bps in preclinical testing with its 421-electrode* Connexus array. First chronic human implant expected H1 2026. (*Single module; full Connexus system links up to four modules for 1,600 channels at full deployment.)
@merge closed a $252 million seed round led by OpenAI in January 2026 at an $850 million valuation. Pursuing non-invasive sonogenetics. Stealth mode, no public product timeline released yet.
Neuracle Medical Technology secured the world’s first regulatory approval for an implantable BCI in March 2026 (NMPA clearance for its NEO device).
Stairmed Technology is the most heavily capitalized invasive Chinese player after a $72.5 million round backed by Alibaba and Tencent.
BrainCo Inc leads non-invasive BCI globally with scaled products in education and prosthetics; closed a $286 million Series B-II round in January 2026 at a $1.3B pre- IPO valuation, with a Hong Kong IPO targeted.
Analysis and map from Dargentic's BRAIN-COMPUTER INTERFACES: THE TAKEOFF ERA Report, Released April 2026 (data cut off 31 March 2026).